Combining Antiplatelet and Anticoagulant Therapies

David Holmes, Dean J. Kereiakes, Neal S. Kleiman, David J. Moliterno, Giuseppe Patti, Cindy L. Grines

Research output: Contribution to journalReview article

130 Citations (Scopus)

Abstract

Antiplatelet therapy is the cornerstone for both primary and secondary prevention therapies for ischemic events resulting from coronary atherosclerotic disease. Dual antiplatelet therapy (aspirin plus a thienopyridine, usually clopidogrel) has assumed a central role in the treatment of acute coronary syndromes and after coronary stent deployment. In addition to antiplatelet therapy, anticoagulant therapy might be indicated for stroke prevention in a variety of conditions that include atrial fibrillation, profound left ventricular dysfunction, and after mechanical prosthetic heart valve replacement. For this reason, the use of triple antithrombotic therapy (a dual antiplatelet regimen plus warfarin) is expected to become more prominent, given an aging patient population. But although triple therapy can prevent both thromboembolism and stent thrombosis, it is also associated with significant bleeding hazards. Furthermore, when bleeding events do occur, the challenge of balancing the risk of stent thrombosis or stroke and the need for hemostasis requires considerable expertise. It is both prudent and timely to review treatment strategies that employ combinations of antiplatelet and anticoagulant therapies as well as strategies aimed at reducing bleeding risk in patients treated with these therapies.

Original languageEnglish (US)
Pages (from-to)95-109
Number of pages15
JournalJournal of the American College of Cardiology
Volume54
Issue number2
DOIs
StatePublished - Jul 7 2009

Fingerprint

Anticoagulants
Therapeutics
Stents
clopidogrel
Hemorrhage
Thrombosis
Stroke
Thromboembolism
Heart Valves
Left Ventricular Dysfunction
Warfarin
Primary Prevention
Acute Coronary Syndrome
Secondary Prevention
Hemostasis
Atrial Fibrillation
Aspirin
Coronary Disease

Keywords

  • anticoagulant
  • antiplatelet
  • therapies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Holmes, D., Kereiakes, D. J., Kleiman, N. S., Moliterno, D. J., Patti, G., & Grines, C. L. (2009). Combining Antiplatelet and Anticoagulant Therapies. Journal of the American College of Cardiology, 54(2), 95-109. https://doi.org/10.1016/j.jacc.2009.03.044

Combining Antiplatelet and Anticoagulant Therapies. / Holmes, David; Kereiakes, Dean J.; Kleiman, Neal S.; Moliterno, David J.; Patti, Giuseppe; Grines, Cindy L.

In: Journal of the American College of Cardiology, Vol. 54, No. 2, 07.07.2009, p. 95-109.

Research output: Contribution to journalReview article

Holmes, D, Kereiakes, DJ, Kleiman, NS, Moliterno, DJ, Patti, G & Grines, CL 2009, 'Combining Antiplatelet and Anticoagulant Therapies', Journal of the American College of Cardiology, vol. 54, no. 2, pp. 95-109. https://doi.org/10.1016/j.jacc.2009.03.044
Holmes, David ; Kereiakes, Dean J. ; Kleiman, Neal S. ; Moliterno, David J. ; Patti, Giuseppe ; Grines, Cindy L. / Combining Antiplatelet and Anticoagulant Therapies. In: Journal of the American College of Cardiology. 2009 ; Vol. 54, No. 2. pp. 95-109.
@article{a2a98db7406b4126aacd51bbd9b1367c,
title = "Combining Antiplatelet and Anticoagulant Therapies",
abstract = "Antiplatelet therapy is the cornerstone for both primary and secondary prevention therapies for ischemic events resulting from coronary atherosclerotic disease. Dual antiplatelet therapy (aspirin plus a thienopyridine, usually clopidogrel) has assumed a central role in the treatment of acute coronary syndromes and after coronary stent deployment. In addition to antiplatelet therapy, anticoagulant therapy might be indicated for stroke prevention in a variety of conditions that include atrial fibrillation, profound left ventricular dysfunction, and after mechanical prosthetic heart valve replacement. For this reason, the use of triple antithrombotic therapy (a dual antiplatelet regimen plus warfarin) is expected to become more prominent, given an aging patient population. But although triple therapy can prevent both thromboembolism and stent thrombosis, it is also associated with significant bleeding hazards. Furthermore, when bleeding events do occur, the challenge of balancing the risk of stent thrombosis or stroke and the need for hemostasis requires considerable expertise. It is both prudent and timely to review treatment strategies that employ combinations of antiplatelet and anticoagulant therapies as well as strategies aimed at reducing bleeding risk in patients treated with these therapies.",
keywords = "anticoagulant, antiplatelet, therapies",
author = "David Holmes and Kereiakes, {Dean J.} and Kleiman, {Neal S.} and Moliterno, {David J.} and Giuseppe Patti and Grines, {Cindy L.}",
year = "2009",
month = "7",
day = "7",
doi = "10.1016/j.jacc.2009.03.044",
language = "English (US)",
volume = "54",
pages = "95--109",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Combining Antiplatelet and Anticoagulant Therapies

AU - Holmes, David

AU - Kereiakes, Dean J.

AU - Kleiman, Neal S.

AU - Moliterno, David J.

AU - Patti, Giuseppe

AU - Grines, Cindy L.

PY - 2009/7/7

Y1 - 2009/7/7

N2 - Antiplatelet therapy is the cornerstone for both primary and secondary prevention therapies for ischemic events resulting from coronary atherosclerotic disease. Dual antiplatelet therapy (aspirin plus a thienopyridine, usually clopidogrel) has assumed a central role in the treatment of acute coronary syndromes and after coronary stent deployment. In addition to antiplatelet therapy, anticoagulant therapy might be indicated for stroke prevention in a variety of conditions that include atrial fibrillation, profound left ventricular dysfunction, and after mechanical prosthetic heart valve replacement. For this reason, the use of triple antithrombotic therapy (a dual antiplatelet regimen plus warfarin) is expected to become more prominent, given an aging patient population. But although triple therapy can prevent both thromboembolism and stent thrombosis, it is also associated with significant bleeding hazards. Furthermore, when bleeding events do occur, the challenge of balancing the risk of stent thrombosis or stroke and the need for hemostasis requires considerable expertise. It is both prudent and timely to review treatment strategies that employ combinations of antiplatelet and anticoagulant therapies as well as strategies aimed at reducing bleeding risk in patients treated with these therapies.

AB - Antiplatelet therapy is the cornerstone for both primary and secondary prevention therapies for ischemic events resulting from coronary atherosclerotic disease. Dual antiplatelet therapy (aspirin plus a thienopyridine, usually clopidogrel) has assumed a central role in the treatment of acute coronary syndromes and after coronary stent deployment. In addition to antiplatelet therapy, anticoagulant therapy might be indicated for stroke prevention in a variety of conditions that include atrial fibrillation, profound left ventricular dysfunction, and after mechanical prosthetic heart valve replacement. For this reason, the use of triple antithrombotic therapy (a dual antiplatelet regimen plus warfarin) is expected to become more prominent, given an aging patient population. But although triple therapy can prevent both thromboembolism and stent thrombosis, it is also associated with significant bleeding hazards. Furthermore, when bleeding events do occur, the challenge of balancing the risk of stent thrombosis or stroke and the need for hemostasis requires considerable expertise. It is both prudent and timely to review treatment strategies that employ combinations of antiplatelet and anticoagulant therapies as well as strategies aimed at reducing bleeding risk in patients treated with these therapies.

KW - anticoagulant

KW - antiplatelet

KW - therapies

UR - http://www.scopus.com/inward/record.url?scp=67649414486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649414486&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2009.03.044

DO - 10.1016/j.jacc.2009.03.044

M3 - Review article

C2 - 19573725

AN - SCOPUS:67649414486

VL - 54

SP - 95

EP - 109

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -